OpenEvidence The leading medical information platform An Official AI Partner of The New England Journal of Medicine OpenEvidence content includes figures, tables, multimedia and full-text clinical findings from The New England Journal of Medicine
OpenEvidence America's Official Medical Knowledge Platform OpenEvidence is the leading medical platform for healthcare professionals, featuring answers grounded in peer-reviewed research from NEJM, JAMA, NCCN, Cochrane, and more
About | OpenEvidence America's Official Medical Knowledge Platform OpenEvidence is the leading medical platform for healthcare professionals, featuring answers grounded in peer-reviewed research from NEJM, JAMA, NCCN, Cochrane, and more
Announcements - OpenEvidence The American Diabetes Association and OpenEvidence Collaborate to Accelerate Evidence-Based Guideline Delivery December 3, 2025
OpenEvidence 2. 0 Now Available We are excited to announce OpenEvidence 2 0 In addition to medical search, OpenEvidence now fully supports administrative and clinical workflow use cases, including:
OpenEvidence and NEJM Group, publisher of the New England Journal of . . . CAMBRIDGE, MA, February 19, 2025 – OpenEvidence, the fastest-growing platform for doctors, has signed a multi-year content agreement with NEJM Group, publisher of the New England Journal of Medicine (NEJM) Under this agreement, all published content and multimedia from 1990 forward from NEJM, NEJM Evidence, NEJM AI, NEJM Catalyst, and NEJM Journal Watch will be provided to OpenEvidence to
OpenEvidence The leading medical information platform
OpenEvidence AI becomes the first AI in history to score above 90% on . . . OpenEvidence AI, the large language model-based artificial intelligence powering the automatic ingestion, analysis, synthesis, and research on openevidence com, has reached a new milestone as the first AI to score over 90% on the United States Medical Licensing Examination (USMLE) OpenEvidence makes 77% fewer errors on the US Medical Licensing Exam than ChatGPT, 24% fewer errors than GPT-4
OpenEvidence to Become a Mayo Clinic Platform Accelerate Company OpenEvidence, an AI company pursuing foundational work in aligning Large Language Models (LLMs) to the medical domain, announced today it is to become a Mayo Clinic Platform Accelerate company As part of Mayo Clinic Platform Accelerate, OpenEvidence will collaborate with Mayo Clinic Platform to improve how health care information is structured and discovered